Search Result
Results for "
VC
" in MedChemExpress (MCE) Product Catalog:
2
Biochemical Assay Reagents
1
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-15742
-
-
-
- HY-147094
-
|
ADC Linker
|
Cancer
|
vc-PABC-DM1 used to synthesize an ADC molecule based on utilize disulfide linker. vc-PABC-DM1 can be used to explore serum stability .
|
-
-
- HY-128957
-
SYD985
|
Drug-Linker Conjugates for ADC
|
Cancer
|
Vc-seco-DUBA (SYD985) is a agent-linker conjugate for ADC with potent antitumor activity by using DUBA (DNA alkylating agent), linked via the ADC linker Vc-seco .
|
-
-
- HY-147093
-
|
ADC Linker
|
Cancer
|
vc-PAB-DMEA-PNU159682 (compound I.47) can be used to synthesize the ADC molecule based on Sulfomaleimide-based Linker. vc-PAB-DMEA-PNU159682 has good serum stability .
|
-
-
- HY-156616
-
|
Liposome
|
Inflammation/Immunology
|
VC1052 is the component of HY-142998 Vaxfectin. Vaxfectin is a cationic lipid-based adjuvant that can be used for plasmid DNA- and protein-based vaccines .
|
-
-
- HY-P1265
-
VC1.1
|
nAChR
|
Neurological Disease
|
ACV1 (Vc1.1), an α-Conotoxin, is a selective α9α10 nAChR antagonist with an IC50 of 19 nM. ACV1 is ~100-fold less potent on human α9α10 vs. rat nAChRs .
|
-
-
- HY-15575
-
VcMMAE
Maximum Cited Publications
44 Publications Verification
MC-Val-Cit-PAB-MMAE; mc-VC-PAB-MMAE
|
Drug-Linker Conjugates for ADC
Microtubule/Tubulin
|
Cancer
|
VcMMAE (mc-vc-PAB-MMAE) is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc).
|
-
-
- HY-112786
-
VC-MMAF
|
Drug-Linker Conjugates for ADC
|
Cancer
|
MC-Val-Cit-PAB-MMAF (Vc-MMAF) is a agent-linker conjugate for ADC by using the tubulin inhibitor, MMAF, linked via cathepsin cleavable MC-Val-Cit-PAB. MC-Val-Cit-PAB-MMAF shows antitumor activity .
|
-
-
- HY-15575S
-
MC-Val-Cit-PAB-MMAE-d8; mc-VC-PAB-MMAE-d8
|
Drug-Linker Conjugates for ADC
Microtubule/Tubulin
|
Cancer
|
VcMMAE-d8 is an isotope of VcMMAE (HY-15575). VcMMAE-d8 is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc) .
|
-
-
- HY-15575G
-
MC-Val-Cit-PAB-MMAE; mc-VC-PAB-MMAE
|
Drug-Linker Conjugates for ADC
|
Cancer
|
VcMMAE (MC-Val-Cit-PAB-MMAE) (GMP) is VcMMAE (HY-15575) produced by using GMP guidelines. VcMMAE is a drug-linker conjugate for ADC .
|
-
-
- HY-136289
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
MB-VC-MGBA is a agent-linker conjugate for ADC with potent antitumor activity by using MGBA (minor-groove-binding DNA-alkylating agent), linked via the ADC linker MB-VC .
|
-
-
- HY-145951
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
Amidate-VC-PAB-MMAF consists a cleavable ADC linker (Amidate-VC-PAB) and a potent tubulin polymerization inhibitor (MMAF). Amidate-VC-PAB-MMAF can be used in the synthesis of antibody-drug conjugates (ADCs). Amidate-VC-PAB-MMAF reduces off-target cytotoxicity of ADCs .
|
-
-
- HY-131085
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
Desmethyl Vc-seco-DUBA consists a cleavable ADC linker (Desmethyl Vc-seco) and a DNA alkylating agent (DUBA). Desmethyl Vc-seco-DUBA can be used in the synthesis of antibody-drug conjugates (ADCs) .
|
-
-
- HY-148461
-
|
ADC Linker
|
Cancer
|
Mal-VC-PAB-PNP is a cleavable ADC linker. Mal-VC-PAB-PNP can be used in the synthesis of antibody-drug conjugates (ADCs) .
|
-
-
- HY-157544
-
-
-
- HY-131057
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
Mc-VC-PAB-SN38 consists a cleavable ADC linker (Mc-VC-PAB) and a DNA topoisomerase I inhibitor (SN38). Mc-VC-PAB-SN38 can be used in the synthesis of antibody-drug conjugates (ADCs) .
|
-
-
- HY-131056
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
Gly3-VC-PAB-MMAE consists a cleavable ADC linker (Gly3-VC-PAB) and a potent tubulin inhibitor (MMAE). Gly3-VC-PAB-MMAE can be used in the synthesis of antibody-drug conjugates (ADCs) .
|
-
-
- HY-136316
-
-
-
- HY-126692
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
Mal-VC-PAB-ABAEP-Azonafide is a agent-linker conjugate for ADC with with potent antitumor activity by using Azonafide (a cytotoxin), linked via the ADC linker Mal-VC-PAB .
|
-
-
- HY-126681
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
SC-VC-PAB-MMAE is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the cleavable linker SC-VC-PAB .
|
-
-
- HY-153601
-
|
Drug-Linker Conjugates for ADC
DNA/RNA Synthesis
|
Cancer
|
MC-VC-PAB-Cyclohexanediamine-Thailanstatin A is a Spliceostatin (HY-16466) analog, and a drug-linker conjugates for ADC, consisting of ADC Cytotoxin Thailanstatin A (HY-129589) and cleavable ADC linker (MC-vc-PAB). MC-VC-PAB-Cyclohexanediamine-Thailanstatin A can be used for ADC synthesis .
|
-
-
- HY-141833
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
Bi-Mc-VC-PAB-MMAE consists ADCs linker (Fmoc-Val-Cit-PAB) and potent tubulin inhibitor (MMAE). Bi-Mc-VC-PAB-MMAE is a agent-linker conjugate for ADC.
|
-
-
- HY-125777A
-
|
nAChR
|
Neurological Disease
|
α-Conotoxin Vc1.1 TFA is a disulfide-bonded peptide isolated from Conus victoriae and is a selective nAChR antagonist. α-Conotoxin Vc1.1 TFA inhibits α3α5β2, α3β2 and α3β4 with IC50s of 7.2 μM, 7.3 μM and 4.2 μM, respectively, and has less inhibitory effect on other nAChR subtypes. α-Conotoxin Vc1.1 TFA has the potential for neuropathic pain reserach .
|
-
-
- HY-111012
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
DBCO-(PEG)3-VC-PAB-MMAE is a agent-linker conjugate for ADC. DBCO-(PEG)3-VC-PAB-MMAE is made by Monomethyl auristatin E (HY-15162) conjugats to DBCO-(PEG)3-vc-PAB linker. DBCO-(PEG)3-VC-PAB-MMAE can be used for the research of cancer . DBCO-(PEG)3-VC-PAB-MMAE is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
|
-
-
- HY-128955
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
MC-VC-PABC-Aur0101 is a agent-linker conjugate for ADC with potent antitumor activity by using Aur0101 (an auristatin microtubule inhibitor), linked via the ADC linker MC-VC-PABC.
|
-
-
- HY-136315
-
-
-
- HY-126693
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
SC-VC-PAB-DM1 is a agent-linker conjugate for ADC with with potent antitumor activity by using DM1 (Mertansine, a tubulin inhibitor) , linked via the ADC linker SC-VC-PAB .
|
-
-
- HY-128897
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
MC-VC-PABC-DNA31 is a agent-linker conjugate for ADC with potent antitumor activity by using DNA31 (a potent RNA polymerase inhibitor), linked via the ADC linker MC-VC-PABC.
|
-
-
- HY-147006
-
|
Others
|
Cancer
|
MT-VC-ZD02044 is a cytotoxic and anti-mitotic agent .
|
-
-
- HY-160234
-
|
ADC Linker
|
Cancer
|
mc-vc-PAB-PBD is a drug linker for the preparation of TDC and ADC .
|
-
-
- HY-126682
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
Mal-VC-PAB-DM1 is a agent-linker conjugate for ADC with potent antitumor activity by using DM1 (a potent microtubule-disrupting agent), linked via the ADC linker Mal-VC-PAB .
|
-
-
- HY-136313
-
-
-
- HY-128910
-
|
Drug-Linker Conjugates for ADC
Microtubule/Tubulin
|
Cancer
|
MC-VC(S)-PABQ-Tubulysin M is a synthetic ADC drug-linker conjugate composed of the tubulin polymerization inhibitor Tubulysin M (an ADC Cytotoxin) (HY-N7053) and MC-VC(S)- PABQ (an ADC linker) is connected. MC-VC(S)-PABQ-Tubulysin M is effective against multidrug-resistant lymphoma cell lines and tumors .
|
-
-
- HY-148057
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
TCO-PEG4-VC-PAB-MMAE is a agent-linker conjugate for ADC. TCO-PEG4-VC-PAB-MMAE contains a cleavable ADC linker (TCO-PEG4-VC-PA) and a potent tubulin inhibitor MMAE (HY-15162) . TCO-PEG4-VC-PAB-MMAE is a click chemistry reagent, it contains a TCO group that can undergo an inverse electron demand Diels-Alder reaction (iEDDA) with molecules containing Tetrazine groups.
|
-
-
- HY-111554
-
-
-
- HY-126668
-
|
ADC Linker
|
Cancer
|
Mal-PEG4-VC-PAB-DMEA is a cleavable ADC linker containing a Maleimide group. Mal-PEG4-VC-PAB-DMEA is used in the synthesis of antibody-drug conjugates (ADCs) .
|
-
-
- HY-153976
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
Fmoc-Gly3-VC-PAB-MMAE is a Drug-Linker Conjugates for ADC. Fmoc-Gly3-VC-PAB-MMAE consists of Monomethyl auristatin E (HY-15162) and a linker .
|
-
-
- HY-136314
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
DBCO-PEG4-VC-PAB-MMAE consists a ADC linker (DBCO-PEG4-VC-PAB) and a tubulin polymerization inhibitor MMAE (HY-15162). DBCO-PEG4-VC-PAB-MMAE can be used in the synthesis of antibody-agent conjugates (ADCs). MMAE is a synthetic derivative of dolastatin 10 and functions as a potent mitotic inhibitor by inhibiting tubulin polymerization. DBCO-PEG4-VC-PAB-MMAE is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
|
-
-
- HY-148399
-
-
-
- HY-163099
-
|
Drug-Linker Conjugates for ADC
Topoisomerase
|
Cancer
|
P5(PEG24)-VC-PAB-exatecan is a camptothecin-based linker-payload platform based on the highly potent camptothecin derivative exatecan. P5(PEG24)-VC-PAB-exatecan has linker-payload structures. P5(PEG24)-VC-PAB-exatecan can be used for the research of tumor .
|
-
-
- HY-140152
-
|
ADC Linker
|
Cancer
|
BCN-PEG3-VC-PFP ester is a cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . BCN-PEG3-VC-PFP ester is a click chemistry reagent, it contains a BCN group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
|
-
-
- HY-126686
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
Mal-Phe-C4-VC-PAB-MMAE is made by MMAE conjugated to Mal-Phe-C4-VC-PAB linker. Monomethyl auristatin E (MMAE), a potent tubulin inhibitor, is a toxin payload in antibody agent conjugate.
|
-
-
- HY-148528
-
|
Others
|
Cancer
|
SC-VC-PAB-N-Me-L-Ala-Maytansinol (compound B1) can be used to synthesis MCC-Maytansinoid A. SC-VC-PAB-N-Me-L-Ala-Maytansinol can be used as a control compound for the cancer research .
|
-
-
- HY-136132
-
|
ADC Linker
|
Cancer
|
MC-VC-PAB-NH2 is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .
|
-
-
- HY-136288
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
Azide-PEG4-VC-PAB-Doxorubicin is a agent-linker conjugate composed of a cytotoxic anthracycline antibiotic Doxorubicin and a linker Azide-PEG4-VC-PAB to make antibody agent conjugate (ADC) . Azide-PEG4-VC-PAB-Doxorubicin is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.
|
-
-
- HY-126690
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
DBCO-(PEG2-VC-PAB-MMAE)2 is made by MMAE conjugated to the cleavable DBCO-(PEG2-VC-PAB)2 linker. Monomethyl auristatin E (MMAE), a potent tubulin inhibitor, is a toxin payload in antibody agent conjugate . DBCO-(PEG2-VC-PAB-MMAE)2 is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
|
-
-
- HY-126684
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
Mal-PEG4-VC-PAB-DMEA-Seco-Duocarmycin SA is a agent-linker conjugate for ADC by using the antitumor antibiotic, Duocarmycin SA, linked via Mal-PEG4-VC-PAB-DMEA-Seco.
|
-
-
- HY-153428
-
-
-
- HY-131089
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
MC-VC-PABC-C6-alpha-Amanitin is an antibody agent conjugate consisting of an anticancer toxin alpha-Amanitin (HY-19610) and a monoclonal antibody MC-VC-PABC-C6. Among them, alpha-Amanitin is a potent inhibitor of RNA polymerase IIα. MC-VC-PABC-C6-alpha-Amanitin accurately targets HER2 receptors, specifically recognizes HER2-positive tumor cells. It is widely used in breast cancer and gastric cancer research .
|
-
-
- HY-136132A
-
|
ADC Linker
|
Cancer
|
MC-VC-PAB-NH2 TFA is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .
|
-
- HY-157465
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
MA-PEG4-VC-PAB-DMEA-duocarmycin DM is a drug-linker conjugate for ADC by using the anticancer antibiotic Duocarmycin DM (HY-130978), linked via MA-PEG4-vc-PAB-DMEA (HY-126668) .
|
-
- HY-153739
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
N3-PEG3-VC-PAB-MMAF (Comp T-88-5) is a drug-linker conjugate containing the ADC linker N3-PEG3-VC-PAB and the tubulin inhibitor MMAF . N3-PEG3-VC-PAB-MMAF is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.
|
-
- HY-48668
-
|
ADC Linker
|
Cancer
|
AcLys-PABC-VC-Aur0101 intermediate-1 is a cathepsin cleavable ADC linker that is used for making antibody-drug conjugate .
|
-
- HY-100874
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
N3-PEG3-vc-PAB-MMAE is a synthesized agent-linker conjugate for ADC that incorporates the MMAE (a tubulin inhibitor ) and 3-unit PEG linker. N3-PEG3-vc-PAB-MMAE shows potent antitumor activity. N3-PEG3-vc-PAB-MMAE is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.
|
-
- HY-126691
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
DBCO-PEG4-VC-PAB-DMEA-PNU-159682, a agent-linker conjugate for ADC, consists the ADC linker DBCO-PEG4-VC-PAB and a potent ADC cytotoxin DMEA-PNU-159682. DMEA-PNU-159682 includes metabolites of nemorubicin (MMDX) from liver microsomes and ADC cytotoxin PNU-159682. DBCO-PEG4-VC-PAB-DMEA-PNU-159682 is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
|
-
- HY-126687
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
Mal-PEG4-VC-PAB-DMEA-PNU-159682, a agent-linker conjugate for ADC, consists the ADC linker Mal-PEG4-VC-PAB and a potent ADC cytotoxin DMEA-PNU-159682. DMEA-PNU-159682 includes metabolites of nemorubicin (MMDX) from liver microsomes and ADC cytotoxin PNU-159682 .
|
-
- HY-160143
-
-
- HY-148426
-
-
- HY-126689
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
Mal-Phe-C4-VC-PAB-DMEA-PNU-159682, a agent-linker conjugate for ADC, consists the ADC linker Mal-Phe-C4-VC-PAB and a potent ADC cytotoxin DMEA-PNU-159682. DMEA-PNU-159682 includes metabolites of nemorubicin (MMDX) from liver microsomes and ADC cytotoxin PNU-159682 .
|
-
- HY-145448
-
-
- HY-148460
-
|
Drug-Linker Conjugates for ADC
EGFR
STING
|
Cancer
|
Mal-VC-PAB-(N-Me-amide-C3)-ADU-S100 triethylamine is an immune stimulator antibody conjugate (ISAC) comprising an anti-human epidermal growth factor receptor 2 (HER2) antibody, a STING agonist (ADU-S100) and a linker. Mal-VC-PAB-(N-Me-amide-C3)-ADU-S100 triethylamine can be uesd for cancer research (WO2018200812A1; example 5) .
|
-
- HY-126677
-
|
ADC Linker
PROTAC Linkers
|
Cancer
|
Boc-NH-PEG3-C2-triazole-DBCO-PEG4-VC-PAB-DMEA is a double claevable 3-unit and 4-unit PEG linker for antibody-agent-conjugation (ADC). Boc-NH-PEG3-C2-triazole-DBCO-PEG4-VC-PAB-DMEA also is a PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-157407
-
-
- HY-106583
-
Cinnoxicam; SPA-S-510; Sinartol
|
COX
|
Inflammation/Immunology
|
Piroxicam cinnamate (Cinnoxicam) is a cyclooxygenase (COX) inhibitor, with anti-inflammatory activity. Piroxicam cinnamate is stable under gastric conditions, can be used for inflammatory-degenerative osteoarticular diseases, rheumatic disorders, and varicocele (VC) associated oligoasthenospermia research .
|
-
- HY-P99829
-
PF-06647020; ABBV-647; h6M24-VC0101
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
Cofetuzumab pelidotin (PF-06647020) is a PTK7-targeting ADC comprising a humanized anti-PTK7 mAb (hu6M024, IgG1) joined to an auristatin microtubule inhibitor payload, auristatin-0101 (Aur0101; HY-12522), by a cleavable valine-citrulline (vc)-based linker. Cofetuzumab pelidotin has a DAR of 4. Cofetuzumab pelidotin binds to cell-surface PTK7 with an EC50 of 1153 pM by flow cytometry. Cofetuzumab pelidotin has the potential for solid tumors research .
|
-
- HY-W014606
-
-
- HY-W015370
-
-
- HY-112099
-
|
ADC Linker
|
Cancer
|
Mc-Val-Cit-PAB-Cl is a cleavable ADC linker. Mc-Val-Cit-PAB-Cl can be used to conjugate MMAE and antibody to form antibody-MC-vc-MMAE (e.g., anti-CD22-MC-VC-PABC-MMAE with IC50s of 3.3 and 0.95 nM for BJAB and WSU cell lines in cytotoxicity assay).
|
-
- HY-141604
-
-
- HY-138822
-
2,3-DPG pentasodium salt
|
Others
|
Cardiovascular Disease
|
2,3-Diphospho-D-glyceric acid pentasodium salt is a highly anionic polyphosphorus compound. 2,3-Diphospho-D-glyceric acid is present in the concave center of red blood cells, it binds hemoglobin to reduce its oxygen affinity. 2,3-Diphospho-D-glyceric acid is an endogenous, selective inhibitor of vascular calcification (VC) and significantly delays the formation of crystalline calpain particles (CPP). 2,3-Diphospho-D-glyceric acid also inhibits calcification in mouse vascular smooth muscle cell line (MOVAS) without cytotoxic effects .
|
-
Cat. No. |
Product Name |
Type |
-
- HY-15575G
-
MC-Val-Cit-PAB-MMAE (GMP); mc-VC-PAB-MMAE (GMP)
|
Fluorescent Dye
|
VcMMAE (MC-Val-Cit-PAB-MMAE) (GMP) is VcMMAE (HY-15575) produced by using GMP guidelines. VcMMAE is a drug-linker conjugate for ADC .
|
Cat. No. |
Product Name |
Type |
-
- HY-15575G
-
MC-Val-Cit-PAB-MMAE (GMP); mc-VC-PAB-MMAE (GMP)
|
Biochemical Assay Reagents
|
VcMMAE (MC-Val-Cit-PAB-MMAE) (GMP) is VcMMAE (HY-15575) produced by using GMP guidelines. VcMMAE is a drug-linker conjugate for ADC .
|
-
- HY-156616
-
|
Drug Delivery
|
VC1052 is the component of HY-142998 Vaxfectin. Vaxfectin is a cationic lipid-based adjuvant that can be used for plasmid DNA- and protein-based vaccines .
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P1265
-
VC1.1
|
nAChR
|
Neurological Disease
|
ACV1 (Vc1.1), an α-Conotoxin, is a selective α9α10 nAChR antagonist with an IC50 of 19 nM. ACV1 is ~100-fold less potent on human α9α10 vs. rat nAChRs .
|
-
- HY-125777A
-
|
nAChR
|
Neurological Disease
|
α-Conotoxin Vc1.1 TFA is a disulfide-bonded peptide isolated from Conus victoriae and is a selective nAChR antagonist. α-Conotoxin Vc1.1 TFA inhibits α3α5β2, α3β2 and α3β4 with IC50s of 7.2 μM, 7.3 μM and 4.2 μM, respectively, and has less inhibitory effect on other nAChR subtypes. α-Conotoxin Vc1.1 TFA has the potential for neuropathic pain reserach .
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P99829
-
PF-06647020; ABBV-647; h6M24-VC0101
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
Cofetuzumab pelidotin (PF-06647020) is a PTK7-targeting ADC comprising a humanized anti-PTK7 mAb (hu6M024, IgG1) joined to an auristatin microtubule inhibitor payload, auristatin-0101 (Aur0101; HY-12522), by a cleavable valine-citrulline (vc)-based linker. Cofetuzumab pelidotin has a DAR of 4. Cofetuzumab pelidotin binds to cell-surface PTK7 with an EC50 of 1153 pM by flow cytometry. Cofetuzumab pelidotin has the potential for solid tumors research .
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
Cat. No. |
Product Name |
Chemical Structure |
-
- HY-15575S
-
|
VcMMAE-d8 is an isotope of VcMMAE (HY-15575). VcMMAE-d8 is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc) .
|
-
Cat. No. |
Product Name |
|
Classification |
-
- HY-111012
-
|
|
DBCO
|
DBCO-(PEG)3-VC-PAB-MMAE is a agent-linker conjugate for ADC. DBCO-(PEG)3-VC-PAB-MMAE is made by Monomethyl auristatin E (HY-15162) conjugats to DBCO-(PEG)3-vc-PAB linker. DBCO-(PEG)3-VC-PAB-MMAE can be used for the research of cancer . DBCO-(PEG)3-VC-PAB-MMAE is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
|
-
- HY-148057
-
|
|
TCO
ADC Synthesis
|
TCO-PEG4-VC-PAB-MMAE is a agent-linker conjugate for ADC. TCO-PEG4-VC-PAB-MMAE contains a cleavable ADC linker (TCO-PEG4-VC-PA) and a potent tubulin inhibitor MMAE (HY-15162) . TCO-PEG4-VC-PAB-MMAE is a click chemistry reagent, it contains a TCO group that can undergo an inverse electron demand Diels-Alder reaction (iEDDA) with molecules containing Tetrazine groups.
|
-
- HY-136314
-
|
|
DBCO
|
DBCO-PEG4-VC-PAB-MMAE consists a ADC linker (DBCO-PEG4-VC-PAB) and a tubulin polymerization inhibitor MMAE (HY-15162). DBCO-PEG4-VC-PAB-MMAE can be used in the synthesis of antibody-agent conjugates (ADCs). MMAE is a synthetic derivative of dolastatin 10 and functions as a potent mitotic inhibitor by inhibiting tubulin polymerization. DBCO-PEG4-VC-PAB-MMAE is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
|
-
- HY-163099
-
|
|
Alkynes
|
P5(PEG24)-VC-PAB-exatecan is a camptothecin-based linker-payload platform based on the highly potent camptothecin derivative exatecan. P5(PEG24)-VC-PAB-exatecan has linker-payload structures. P5(PEG24)-VC-PAB-exatecan can be used for the research of tumor .
|
-
- HY-140152
-
|
|
BCN
ADC Synthesis
|
BCN-PEG3-VC-PFP ester is a cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . BCN-PEG3-VC-PFP ester is a click chemistry reagent, it contains a BCN group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
|
-
- HY-136288
-
|
|
Azide
|
Azide-PEG4-VC-PAB-Doxorubicin is a agent-linker conjugate composed of a cytotoxic anthracycline antibiotic Doxorubicin and a linker Azide-PEG4-VC-PAB to make antibody agent conjugate (ADC) . Azide-PEG4-VC-PAB-Doxorubicin is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.
|
-
- HY-126690
-
|
|
DBCO
|
DBCO-(PEG2-VC-PAB-MMAE)2 is made by MMAE conjugated to the cleavable DBCO-(PEG2-VC-PAB)2 linker. Monomethyl auristatin E (MMAE), a potent tubulin inhibitor, is a toxin payload in antibody agent conjugate . DBCO-(PEG2-VC-PAB-MMAE)2 is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
|
-
- HY-153486
-
|
|
Azide
|
N3-VC-PAB-PNP is the intermediate of bicyclic peptide ligand STING conjugates . N3-VC-PAB-PNP is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.
|
-
- HY-153739
-
|
|
Azide
|
N3-PEG3-VC-PAB-MMAF (Comp T-88-5) is a drug-linker conjugate containing the ADC linker N3-PEG3-VC-PAB and the tubulin inhibitor MMAF . N3-PEG3-VC-PAB-MMAF is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.
|
-
- HY-100874
-
|
|
Azide
|
N3-PEG3-vc-PAB-MMAE is a synthesized agent-linker conjugate for ADC that incorporates the MMAE (a tubulin inhibitor ) and 3-unit PEG linker. N3-PEG3-vc-PAB-MMAE shows potent antitumor activity. N3-PEG3-vc-PAB-MMAE is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.
|
-
- HY-126691
-
|
|
DBCO
|
DBCO-PEG4-VC-PAB-DMEA-PNU-159682, a agent-linker conjugate for ADC, consists the ADC linker DBCO-PEG4-VC-PAB and a potent ADC cytotoxin DMEA-PNU-159682. DMEA-PNU-159682 includes metabolites of nemorubicin (MMDX) from liver microsomes and ADC cytotoxin PNU-159682. DBCO-PEG4-VC-PAB-DMEA-PNU-159682 is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
|
-
- HY-157407
-
|
|
Alkynes
|
Cyclooctyne-O-amido-PEG4-VC-PAB-Gly-Gly-NH-O-CO-Exatecan is a drug-linker conjugate for ADC (ADC Cytotoxin: Exatecan) .
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: